Richmond Pharmacology | London, United Kingdom

Research site

(Unclaimed)

Location

1a Newcomen St, London, London, City of, England

Site insights

Top conditions

Top treatments

FOR-6219

Moxifloxacin

Eplontersen

RV521

UPB-101

INZ-701

Cuprior®

AST-008

ION-682884

Trientine Base

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 43 total trials

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

The goal of this clinical trial is to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participan...

Enrolling

Glanzmann Thrombasthenia

Drug: HMB-001

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.

Enrolling

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Drug: Eplontersen

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC). For more informa...

Active, not recruiting

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Drug: Eplontersen

Drug: Placebo

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics PD) of multiple ascending doses of INZ-7...

Active, not recruiting

ATP-Binding Cassette Subfamily C Member 6 Deficiency

Generalized Arterial Calcification of Infancy

Drug: INZ-701

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of INZ-...

Active, not recruiting

Autosomal Recessive Hypophosphatemic Rickets

Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

Drug: INZ-701

MAGNITUDE: a Phase 3 Study of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.

Enrolling

Transthyretin Amyloidosis (ATTR) with Cardiomyopathy

Drug: Placebo

Biological: NTLA-2001

Multiple Ascending Dose Noribogaine PK/PD in Healthy Volunteers

This trial will be a randomised, double-blind, sequential-group, multiple-dose, placebo-controlled, dose escalation trial to characterise the pharmac...

Enrolling

Pharmacokinetics

Drug: Noribogaine

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Compl...

Active, not recruiting

Amyloid Cardiomyopathy, Transthyretin-Related

Drug: Acoramidis (AG10)

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms